Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up.
Finnish pharmaceutical firm Orion Oyj has signed a loan agreement of €100m with the European Investment Bank in Espoo.
BridgeBio Pharma, a clinical-stage biopharmaceutical firm focused on the development of medicines for genetic diseases, has secured $299.2m funds to advanced its existing drug research and development programs.
British drugmaker GlaxoSmithKline (GSK) has completed the acquisition of the US-based oncology-focused biopharmaceutical firm Tesaro for $5.1bn (£4bn).
Kyn Therapeutics, a US-based clinical-stage biotech company, has entered into a global collaboration with biopharma major Celgene to develop immuno-oncology therapies.
Juvenescence, a biopharmaceutical company focused on modifying ageing and age-related disease, has closed the first tranche of its Series B financing, in the amount of $46m.
Biomunex Pharmaceuticals has signed a licensing agreement with Sanofi for the development of bi-specific and multi-specific antibody therapeutics.
Bioharmony Therapeutics, a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, has entered into a collaborative research and licensing agreement with Boehringer Ingelheim to develop bacteriophage lysins for the treatment of multidrug resistant (MDR) Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections.
Ascletis Pharma (Ascletis, 1672.HK) and Suzhou Alphamab jointly announce that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for anti-PD-L1 KN035 to treat hepatitis B and other viral diseases in Greater China (Ascletis code: ASC22).
Charles River Laboratories International has collaborated with Atomwise on integrated and artificial intelligence (AI)-driven drug discovery.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.